Cargando…

Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden

BACKGROUND: The aim of this study was to provide a descriptive account of carbapenem resistance and risk factors for mortality from invasive Acinetobacter infections in the south of Sweden. METHODS: Blood isolates with growth of Acinetobacter species between 2010 and 2019 in Skåne county were subtyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingefors, Erik, Tverring, Jonas, Nafaa, Fatima, Jönsson, Niklas, Karlsson Söbirk, Sara, Kjölvmark, Charlott, Ljungquist, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667949/
https://www.ncbi.nlm.nih.gov/pubmed/34912503
http://dx.doi.org/10.1080/20008686.2021.2009324
_version_ 1784614466975956992
author Ingefors, Erik
Tverring, Jonas
Nafaa, Fatima
Jönsson, Niklas
Karlsson Söbirk, Sara
Kjölvmark, Charlott
Ljungquist, Oskar
author_facet Ingefors, Erik
Tverring, Jonas
Nafaa, Fatima
Jönsson, Niklas
Karlsson Söbirk, Sara
Kjölvmark, Charlott
Ljungquist, Oskar
author_sort Ingefors, Erik
collection PubMed
description BACKGROUND: The aim of this study was to provide a descriptive account of carbapenem resistance and risk factors for mortality from invasive Acinetobacter infections in the south of Sweden. METHODS: Blood isolates with growth of Acinetobacter species between 2010 and 2019 in Skåne county were subtyped using MALDI-TOF and subjected to susceptibility testing against clinically relevant antibiotics. Association between risk factors and 30-day mortality were analysed in univariate and multivariate logistic regression models. RESULTS: There were 179 bacteraemia episodes in 176 patients included in the study. The 30-day all-cause mortality was 16%. In all, two percent of Acinetobacter strains were carbapenem resistant. Independent risk factors associated with 30-day mortality in the multivariate regression model were Acinetobacter growth in all blood cultures drawn at the day of bacteraemia onset (OR 5.0, 95% CI: 1.8 to 13.7, p= 0.002), baseline functional capacity (1–4 points, OR 2.0, 95% CI: 1.2 to 3.4, p= 0.010) and correct empiric antibiotics at time of culture (OR 3.5 95% CI: 1.0 to 11.8, p= 0.045). CONCLUSION: This study on Acinetobacter bacteraemia in South Sweden found low 30-day mortality and low carbapenem-resistance rates compared to previous international studies which may be due to a higher rate of contaminant findings.
format Online
Article
Text
id pubmed-8667949
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86679492021-12-14 Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden Ingefors, Erik Tverring, Jonas Nafaa, Fatima Jönsson, Niklas Karlsson Söbirk, Sara Kjölvmark, Charlott Ljungquist, Oskar Infect Ecol Epidemiol Research Article BACKGROUND: The aim of this study was to provide a descriptive account of carbapenem resistance and risk factors for mortality from invasive Acinetobacter infections in the south of Sweden. METHODS: Blood isolates with growth of Acinetobacter species between 2010 and 2019 in Skåne county were subtyped using MALDI-TOF and subjected to susceptibility testing against clinically relevant antibiotics. Association between risk factors and 30-day mortality were analysed in univariate and multivariate logistic regression models. RESULTS: There were 179 bacteraemia episodes in 176 patients included in the study. The 30-day all-cause mortality was 16%. In all, two percent of Acinetobacter strains were carbapenem resistant. Independent risk factors associated with 30-day mortality in the multivariate regression model were Acinetobacter growth in all blood cultures drawn at the day of bacteraemia onset (OR 5.0, 95% CI: 1.8 to 13.7, p= 0.002), baseline functional capacity (1–4 points, OR 2.0, 95% CI: 1.2 to 3.4, p= 0.010) and correct empiric antibiotics at time of culture (OR 3.5 95% CI: 1.0 to 11.8, p= 0.045). CONCLUSION: This study on Acinetobacter bacteraemia in South Sweden found low 30-day mortality and low carbapenem-resistance rates compared to previous international studies which may be due to a higher rate of contaminant findings. Taylor & Francis 2021-12-10 /pmc/articles/PMC8667949/ /pubmed/34912503 http://dx.doi.org/10.1080/20008686.2021.2009324 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ingefors, Erik
Tverring, Jonas
Nafaa, Fatima
Jönsson, Niklas
Karlsson Söbirk, Sara
Kjölvmark, Charlott
Ljungquist, Oskar
Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden
title Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden
title_full Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden
title_fullStr Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden
title_full_unstemmed Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden
title_short Low 30-day mortality and low carbapenem-resistance in a decade of Acinetobacter bacteraemia in South Sweden
title_sort low 30-day mortality and low carbapenem-resistance in a decade of acinetobacter bacteraemia in south sweden
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667949/
https://www.ncbi.nlm.nih.gov/pubmed/34912503
http://dx.doi.org/10.1080/20008686.2021.2009324
work_keys_str_mv AT ingeforserik low30daymortalityandlowcarbapenemresistanceinadecadeofacinetobacterbacteraemiainsouthsweden
AT tverringjonas low30daymortalityandlowcarbapenemresistanceinadecadeofacinetobacterbacteraemiainsouthsweden
AT nafaafatima low30daymortalityandlowcarbapenemresistanceinadecadeofacinetobacterbacteraemiainsouthsweden
AT jonssonniklas low30daymortalityandlowcarbapenemresistanceinadecadeofacinetobacterbacteraemiainsouthsweden
AT karlssonsobirksara low30daymortalityandlowcarbapenemresistanceinadecadeofacinetobacterbacteraemiainsouthsweden
AT kjolvmarkcharlott low30daymortalityandlowcarbapenemresistanceinadecadeofacinetobacterbacteraemiainsouthsweden
AT ljungquistoskar low30daymortalityandlowcarbapenemresistanceinadecadeofacinetobacterbacteraemiainsouthsweden